Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2017Vol. 37(4), pp. 401–411
Citations Over TimeTop 10% of 2017 papers
Abstract
Patiromer and ZS-9 represent significant pharmacologic advancements in the treatment of hyperkalemia. Both agents exhibited statistically and clinically significant reductions in potassium for the primary end point of this meta-analysis. Given the adverse effect profile and the observed time-dependent effects, ZS-9 may play more of a role in treating acute hyperkalemia.
Related Papers
- Hyperkalemia revisited.(2006)
- → Profound Hyperkalemia Without Electrocardiographic Manifestations(1986)108 cited
- → What is the Role and Impact of the ECG in the Patient with Hyperkalemia?(2009)2 cited
- → [Prevention and treatment of hyperkalemia in chronic kidney disease].(2021)
- → Disorders of Potassium: Hyperkalemia(2023)